4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0000950170-23-071116
Senior VP, Chief Pharma Dev. sold 4,000 shares at an average $235.50 ($942,000)
- Senior VP, Chief Pharma Dev. acquired 4,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-14 | Option exercise | +2,000 | $87.92 | $175,840 | 7,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-14 | Sale | −1,000 | $233.00 | $233,000 | 6,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-14 | Sale | −1,000 | $232.00 | $232,000 | 5,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-15 | Option exercise | +2,000 | $87.92 | $175,840 | 7,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-15 | Sale | −1,000 | $236.00 | $236,000 | 6,667 | D |
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-15 | Sale | −1,000 | $241.00 | $241,000 | 5,667 | D |
| Derivatives | |||||||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-14 | Option exercise · Stock Option (Right to Buy) | −2,000 | 19,200 | D | ||
| Waltermire Robert E. Senior VP, Chief Pharma Dev. | 2023-12-15 | Option exercise · Stock Option (Right to Buy) | −2,000 | 17,200 | D | ||
| Open-market sales · 4,000 sh · avg $235.50 · $942,000 | |||||||
Loading xslF345X05/ownership.xml…